Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Group A Streptococcus

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

General Information

General InformationGeneral Information

Description

  • group A Streptococcus (GAS) is a ubiquitous human pathogen associated with a broad spectrum of clinical illnesses, including pharyngitis, skin and soft tissue infections (such as cellulitis), and severe invasive or systemic infections (such as toxic shock syndrome)
  • infection with GAS may lead to local suppurative complications such as abscesses but also to nonsuppurative complications such as
    • acute rheumatic fever
    • acute postinfectious glomerulonephritis

References

General references used

  1. Steer AC, Lamagni T, Curtis N, Carapetis JR. Invasive group A streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012 Jun 18;72(9):1213-27OpenInNew
  2. Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov;55(10):e86-e102OpenInNewfull-textOpenInNew
  3. Johansson L, Thulin P, Low DE, Norrby-Teglund A. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin Infect Dis. 2010 Jul 1;51(1):58-65OpenInNewfull-textOpenInNew
  4. Metzgar D, Zampolli A. The M protein of group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence. 2011 Sep-Oct;2(5):402-12OpenInNew
  5. Spaulding AR, Salgado-Pabón W, Kohler PL, Horswill AR, Leung DY, Schlievert PM. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013 Jul;26(3):422-47OpenInNew
  6. Johansson L, Norrby-Teglund A. Immunopathogenesis of streptococcal deep tissue infections. Curr Top Microbiol Immunol. 2013;368:173-88OpenInNew
  7. Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol. 2011 Sep 16;9(10):724-36OpenInNew
  8. Bessen DE. Population biology of the human restricted pathogen, Streptococcus pyogenes. Infect Genet Evol. 2009 Jul;9(4):581-93OpenInNewfull-textOpenInNew

Synthesized Recommendation Grading System for DynaMed

  • DynaMed systematically monitors clinical evidence to continuously provide a synthesis of the most valid relevant evidence to support clinical decision-making (see 7-Step Evidence-Based MethodologyOpenInNew).
  • Guideline recommendations summarized in the body of a DynaMed topic are provided with the recommendation grading system used in the original guideline(s), and allow DynaMed users to quickly see where guidelines agree and where guidelines differ from each other and from the current evidence.
  • In DynaMed (DM), we synthesize the current evidence, current guidelines from leading authorities, and clinical expertise to provide recommendations to support clinical decision-making in the Overview & Recommendations section.
  • We use the Grading of Recommendations Assessment, Development and Evaluation (GRADE)OpenInNew to classify synthesized recommendations as Strong or Weak.
    • Strong recommendations are used when, based on the available evidence, clinicians (without conflicts of interest) consistently have a high degree of confidence that the desirable consequences (health benefits, decreased costs and burdens) outweigh the undesirable consequences (harms, costs, burdens).
    • Weak recommendations are used when, based on the available evidence, clinicians believe that desirable and undesirable consequences are finely balanced, or appreciable uncertainty exists about the magnitude of expected consequences (benefits and harms). Weak recommendations are used when clinicians disagree in judgments of relative benefit and harm, or have limited confidence in their judgments. Weak recommendations are also used when the range of patient values and preferences suggests that informed patients are likely to make different choices.
  • DynaMed (DM) synthesized recommendations (in the Overview & Recommendations section) are determined with a systematic methodology:
    • Recommendations are initially drafted by clinical editors (including ≥ 1 with methodological expertise and ≥ 1 with content domain expertise) aware of the best current evidence for benefits and harms, and the recommendations from guidelines.
    • Recommendations are phrased to match the strength of recommendation. Strong recommendations use "should do" phrasing, or phrasing implying an expectation to perform the recommended action for most patients. Weak recommendations use "consider" or "suggested" phrasing.
    • Recommendations are explicitly labeled as Strong recommendations or Weak recommendations when a qualified group has explicitly deliberated on making such a recommendation. Group deliberation may occur during guideline development. When group deliberation occurs through DynaMed-initiated groups:
      • Clinical questions will be formulated using the PICO (Population, Intervention, Comparison, Outcome) framework for all outcomes of interest specific to the recommendation to be developed.
      • Systematic searches will be conducted for any clinical questions where systematic searches were not already completed through DynaMed content development.
      • Evidence will be summarized for recommendation panel review including for each outcome, the relative importance of the outcome, the estimated effects comparing intervention and comparison, the sample size, and the overall quality rating for the body of evidence.
      • Recommendation panel members will be selected to include at least 3 members that together have sufficient clinical expertise for the subject(s) pertinent to the recommendation, methodological expertise for the evidence being considered, and experience with guideline development.
      • All recommendation panel members must disclose any potential conflicts of interest (professional, intellectual, and financial), and will not be included for the specific panel if a significant conflict exists for the recommendation in question.
      • Panel members will make Strong recommendations if and only if there is consistent agreement in a high confidence in the likelihood that desirable consequences outweigh undesirable consequences across the majority of expected patient values and preferences. Panel members will make Weak recommendations if there is limited confidence (or inconsistent assessment or dissenting opinions) that desirable consequences outweigh undesirable consequences across the majority of expected patient values and preferences. No recommendation will be made if there is insufficient confidence to make a recommendation.
      • All steps in this process (including evidence summaries which were shared with the panel, and identification of panel members) will be transparent and accessible in support of the recommendation.
    • Recommendations are verified by ≥ 1 editor with methodological expertise, not involved in recommendation drafting or development, with explicit confirmation that Strong recommendations are adequately supported.
    • Recommendations are published only after consensus is established with agreement in phrasing and strength of recommendation by all editors.
    • If consensus cannot be reached then the recommendation can be published with a notation of "dissenting commentary" and the dissenting commentary is included in the topic details.
    • If recommendations are questioned during peer review or post publication by a qualified individual, or reevaluation is warranted based on new information detected through systematic literature surveillance, the recommendation is subject to additional internal review.

DynaMed Editorial Process

Special acknowledgements

  • Esther Jolanda van Zuuren, MD (Head of Allergy, Dermatology, and Venereology, Leiden University Medical Centre; Netherlands)
  • Dr. van Zuuren declares no relevant financial conflicts of interest.
  • Alan Ehrlich, MD (Executive Editor; Associate Professor of Family Medicine, University of Massachusetts Medical School; Massachusetts, United States)
  • Dr. Ehrlich declares no relevant financial conflicts of interest.
  • DynaMed topics are written and edited through the collaborative efforts of the above individuals. Deputy Editors, Section Editors, and Topic Editors are active in clinical or academic medical practice. Recommendations Editors are actively involved in development and/or evaluation of guidelines.
  • Editorial Team role definitions
    Topic Editors define the scope and focus of each topic by formulating a set of clinical questions and suggesting important guidelines, clinical trials, and other data to be addressed within each topic. Topic Editors also serve as consultants for the internal DynaMed Editorial Team during the writing and editing process, and review the final topic drafts prior to publication.
    Section Editors have similar responsibilities to Topic Editors but have a broader role that includes the review of multiple topics, oversight of Topic Editors, and systematic surveillance of the medical literature.
    Recommendations Editors provide explicit review of DynaMed Overview and Recommendations sections to ensure that all recommendations are sound, supported, and evidence-based. This process is described in "Synthesized Recommendation Grading."
    Deputy Editors are employees of DynaMed and oversee DynaMed internal publishing groups. Each is responsible for all content published within that group, including supervising topic development at all stages of the writing and editing process, final review of all topics prior to publication, and direction of an internal team.

How to cite

National Library of Medicine, or "Vancouver style" (International Committee of Medical Journal Editors):

  • DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T903304, Group A Streptococcus; [updated 2018 Dec 04, cited place cited date here]. Available from https://www.dynamed.com/topics/dmp~AN~T903304. Registration and login required.
  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Evaluation

    • Management

  • Related Summaries

  • KeyboardArrowRight

    General Information

    • Description

  • KeyboardArrowRight

    Pathogen

    • Classification

    • KeyboardArrowRight

      Virulence factors

      • M protein

      • Superantigens

      • Streptococcal pyrogenic exotoxin B (SpeB)

      • Other virulence factors

    • Habitat

  • KeyboardArrowRight

    Epidemiology

    • Geographic distribution

    • KeyboardArrowRight

      Incidence and prevalence

      • Global incidence and prevalence

      • KeyboardArrowRight

        North American incidence and prevalence

        • Invasive group A streptococcal disease

        • Oropharyngeal carriage and pharyngitis

      • European incidence and prevalence

    • Risk factors

  • KeyboardArrowRight

    Host-Pathogen Interaction

    • Transmission

    • KeyboardArrowRight

      Pathogenesis

      • Colonization

      • Acute and invasive infection

      • Immune evasion

      • Mechanisms of resistance

    • Immune response

  • KeyboardArrowRight

    Clinical Features

    • Streptococcal pharyngitis

    • KeyboardArrowRight

      Skin and soft-tissue infections

      • Impetigo

      • Erysipelas

      • Cellulitis

      • Necrotizing fasciitis

      • Myositis and myonecrosis

    • KeyboardArrowRight

      Systemic infections

      • Puerperal sepsis

      • Scarlet fever

      • Streptococcal toxic shock syndrome

    • KeyboardArrowRight

      Postinfectious nonsuppurative sequelae

      • Acute rheumatic fever and rheumatic heart disease

      • Acute postinfectious glomerulonephritis

      • Other associated conditions

  • KeyboardArrowRight

    Diagnosis

    • Principles of diagnosis

    • Culture

    • Rapid antigen detection tests

    • Serum antibody detection

  • KeyboardArrowRight

    Treatment

    • Principles of treatment

    • Antibiotic susceptibility and resistance

    • Clindamycin efficacy in invasive disease

    • IV immunoglobulin (IVIG)

  • Prognosis

  • KeyboardArrowRight

    Prevention and Infection Control

    • Community measures

    • Institutional measures

    • Immunization

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • United States guidelines

      • European guidelines

    • Review articles

    • MEDLINE search

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Images in topic (1)

View all
Streptococcal superinfection

Streptococcal superinfection

CheckCircle
Subscribe for unlimited access to DynaMed content.
Already subscribed? Sign in

top